Table 1 Baseline patients’ characteristics.
Age at inclusion | |
|---|---|
Median in years (Range) | 54 (30–78) |
ECOG - n patients | |
0 | 46 |
1 | 44 |
Disease type at screening | |
Visceral | 84 |
Non-visceral | 6 |
History of brain metastases - n patients | 20 |
HER2-positivity based on primary tumor - n patients | 84 |
Confirmed by reference lab | 82 |
Not confirmed by reference lab | 2 |
FISH+ only | 4 |
IHC 2+ with FISH+ | 11 |
IHC 3+ with FISH+ | 42 |
IHC 3+ (no FISH+) | 27 |
HER2-positivity based on metastatic biopsy - n patients | 6 |
Confirmed by reference lab | 6 |
Not confirmed by reference lab | 0 |
FISH+ only | 0 |
IHC 2+ with FISH+ | 3 |
IHC 3+ with FISH+ | 2 |
IHC 3+ (no FISH+) | 1 |
Hormone receptor status - n patients | |
ER+ or PR+ or both | 63 |
ER- and PR- | 27 |
Prior systemic therapies for advanced disease | |
Yes - n patients | 83 |
No - n patients | 7 |
Median number of lines (range) | 3 (0–11) |
Median number of lines including trastuzumab (range) | 2 (0–7) |
Tyrosine kinase inhibitor - number of patients | 24 |
Pertuzumab - n patients | 6 |
HSP90 inhibitor - n patients | 4 |
